Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
View Patent ↗Solid dry powder compositions comprising active agents and dextran polymer derivatives comprising an ester-linked amine-containing substituent and an alkyl ester substituent are disclosed, as are methods for making such compositions.
1. A solid dry powder composition comprising:
(a) an active agent; and
(b) a dextran polymer comprising
(i) an ester-linked amine-containing substituent, selected from
and mixtures thereof, wherein R 1 is selected from C 1 , C 2 , C 3 , or C 4 alkyl groups, R 2 and R 3 may be the same or different and are selected from hydrogen, methyl and ethyl groups, and R 4 , R 5 , and R 6 may be the same or different and are selected from methyl and ethyl groups, and wherein the degree of substitution of said ester-linked amine-containing substituent is at least 0.03, and
(ii) an alkyl ester substituent selected from acetate, propionate, butyrate, isobutyrate, and mixtures thereof, wherein the degree of substitution of said alkyl ester substituent is at least 0.05.
2. The composition of claim 1 wherein said ester-linked amine-containing substituent is
wherein R 1 is selected from C 1 , C 2 , C 3 , or C 4 alkyl groups, and R 2 and R 3 may be the same or different and are selected from hydrogen, methyl and ethyl groups.
3. The composition of claim 2 wherein R 1 is a C 2 alkyl group, and R 2 and R 3 are hydrogens.
4. The composition of claim 3 wherein said alkyl ester substituent is propionate.
5. The composition of claim 1 wherein said ester-linked amine-containing substituent is
wherein R 1 is selected from C 1 , C 2 , C 3 , or C 4 alkyl groups, and R 4 , R 5 , and R 6 may be the same or different and are selected from methyl and ethyl groups.
6. The composition of claim 5 wherein R 1 is a C 3 alkyl group, and R 4 , R 5 , and R 6 are methyl groups.
7. The composition of claim 6 wherein said alkyl ester substituent is selected from acetate and propionate.
8. The composition of claim 1 wherein said ester-linked amine-containing substituent has a degree of substitution of at least 0.05.
9. The composition of claim 1 wherein said degree of substitution of said alkyl ester substituent is at least 0.1.
10. The composition of claim 1 wherein said composition is formulated for administration to a human or animal via a mode selected from oral, buccal, mucosal, sublingual, intravenous, intra-arterial, intramuscular, subcutaneous, intraperitoneal, intraarticular, infusion, intrathecal, intraurethral, topical, subdermal, transdermal, intranasal, inhalation, pulmonary tract, intratracheal, intraocular, ocular, intraaural, vaginal, and rectal.
11. The composition of claim 10 wherein said composition is formulated for administration to a human or animal via inhalation.
12. The composition of claim 11 wherein said composition is formulated for delivery to the upper airways.
13. The composition of claim 11 wherein said composition is formulated for delivery to the lower airways.
14. The composition of claim 1 wherein said active agent is selected from a small molecule having a molecular weight of 2000 Daltons or less, a biological active agent, and mixtures thereof.
15. The composition of claim 14 wherein said active agent is a biological active agent selected from proteins, antibodies, antibody fragments, antigens, peptides, oligonucleotides, vaccines, and mixtures thereof.
16. The composition of claim 15 wherein said composition is formulated for delivery to the nasal passages.
17. A method, comprising:
providing a solid dry powder composition formulated for inhalation by a human or animal, the solid dry powder composition comprising an active agent and a dextran polymer comprising
(i) an ester-linked amine-containing substituent, selected from
and mixtures thereof, wherein R 1 is selected from C 1 , C 2 , C 3 , or C 4 alkyl groups, R 2 and R 3 may be the same or different and are selected from hydrogen, methyl and ethyl groups, and R 4 , R 5 , and R 6 may be the same or different and are selected from methyl and ethyl groups, and wherein the degree of substitution of said ester-linked amine-containing substituent is at least 0.03, and
(ii) an alkyl ester substituent selected from acetate, propionate, butyrate, isobutyrate, and mixtures thereof, wherein the degree of substitution of said alkyl ester substituent is at least 0.05.
18. The method of claim 17 wherein said composition is formulated for delivery to the upper airways.
19. The method of claim 17 wherein said composition is formulated for delivery to the lower airways.
20. The method of claim 17 wherein said composition is formulated for delivery to the nasal passages.